ADC Linker Synthesis Service

One of the greatest challenges in the development of antibody-drug conjugates (Antibody-Drug Conjugate, ADCs) is selecting an appropriate Linker to bind the cytotoxic payload to the antibody, forming an integrated drug molecule. The primary role of the Linker is to maintain the stability of the ADC during circulation in the body, ensuring that the drug molecule reaches the target cell intact. Once the ADC binds to the target cell, the Linker will break under appropriate conditions, releasing the cytotoxic drug to exert its therapeutic effect.

ADC Linker is the key factor determining the efficacy and safety of drugs; its design must take into account stability, targeted release, and process feasibility. Currently, cleavable Linker (especially enzyme-cleavable types) have become mainstream due to their high selectivity and potent killing effects, while non-cleavable Linker show unique value in certain specific situations. Merdiv is committed to continuous technological innovation in ADC Linker for solid tumor treatment, overcoming drug resistance, and personalized medicine, driving the rapid development and clinical application of innovative anti-tumor drugs.

(1) Four core advantages

(2) Customized Linker design and screening services

· Provide Linker design based on target characteristics, Payload type and indication requirements, and optimize drug release kinetics using MT-Cleavable Linker technology (such as acid sensitive, enzyme responsive, etc.).

· Establish Linker library, covering different stability, water solubility and cleavage mechanism options, to support customers to quickly screen.